Part 3/10:
Shannon noted that enthusiasm around epacadostat had been mounting following promising Phase 2 results presented at the American Society of Clinical Oncology (ASCO) conference last year. Investors were optimistic about the potential of combining a PD-1 inhibitor with Insight's drug to establish a new standard of care in melanoma treatment. However, the Phase 3 trial results revealed the disappointing reality that the expected benefits were simply not there.